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Abstract
Background: Recent studies indicate an increase in tumor progression and recurrence in head and neck
squamous cell carcinomas (HNSCC) of cancer patients taking recombinant human erythropoietin (rhEpo) for
anemia. This study was undertaken to investigate the potential role of rhEpo in invasion, proliferation, and cisplatin-
induced cell death in HNSCC cell lines.
Methods: The following experiments were performed with two HNSCC cell lines, UMSCC-10B and UMSCC-22B.
Presence of EpoR in both cell lines was determined by western blot and quantitative PCR. Colorimetric MTS assays
and clonogenic assays were used to study the effect of rhEpo at pharmacologically relevant doses on cell
proliferation. Matrigel invasion assays were performed in order to determine effects of exogenous rhEpo on
invasive abilities. Clonogenic assays were also used to study potential cytoprotective effects of rhEpo against
cisplatin. Immunoblotting was done to analyze the effect of rhEpo on Akt phosphorylation. Finally, MTS and TUNEL
assays were performed to test our hypothesis that Akt activation by PI3K was involved in rhEpo-mediated cisplatin
resistance.
Results: HNSCC cell lines were shown to express Epo receptor (EpoR). RhEpo increased invasion 1.8-fold in
UMSCC-10B and 2.6-fold in UMSCC-22B compared to control. RhEpo at 10 U/ml increased cell proliferation by 41%
and 53% in UMSCC-10B and UMSCC-22B, respectively, and colony formation by 1.5-fold and 1.8-fold. UMSCC-10B
treated with cisplatin and exposed to rhEpo at 1 and 10 U/ml resulted in a 1.7-fold and 3.0-fold increase in colony
number compared to control, respectively. UMSCC-22B treated with cisplatin and rhEpo at 1 or 10 U/ml resulted in
~2.5-fold increase in colony number. A TUNEL assay demonstrated a 30.5% and 76.5% increase in survival in
UMSCC-10B and UMSCC-22B cells, respectively, in cisplatin and rhEpo-treated cells compared to cisplatin alone.
MTS assay showed similar cytoprotective effects. Western blot revealed increased phosphorylation of Akt upon
exposure of HNSCC cell lines to rhEpo. MTS assay and TUNEL analyses implicate Akt as a likely contributor to
regulation of rhEpo-mediated cytoprotection.
Conclusions: The results demonstrate that, in HNSCC cells expressing functional EpoR, rhEpo promotes invasion,
cell proliferation, and induces resistance to cisplatin, which may contribute to tumor progression.
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Erythropoiesis stimulating agents (i.e., recombinant
human epoetin alfa) have been widely used to treat ane-
mia. Recombinant human epoetin alfa (rhEpo) is a gly-
coprotein (30.4 kDa) produced by recombinant DNA
technology, and has the same biologic effects as the
endogeneous erythropoietin produced by the kidneys.
RhEpo has been used since 1993 for the treatment of
anemia, including those associated with chemo- and
radiation therapy in cancer patients. Early on, it was
thought that rhEpo exerts its effect(s) exclusively in
hematopoietic tissues, where it plays a crucial role in
the maturation of red blood cells. However, recent stu-
dies have shown expression and function of Epo and
EpoR in a variety of human cancers, including solid
tumors and tumor cell lines [1-3]. As such, treatment
with rhEpo could have unintended pharmacologic con-
sequences. Given the precise role of rhEpo in human
cancers, particularly tumor progression and recurrence,
is not well understood, clinical and basic research stu-
dies are still necessary to define signaling pathways acti-
vated by rhEpo/EpoR within nonhematopoietic cancer
cells.
The presence of EpoR in cancer tissues, if functional,
could have unintended consequences in patients who
use rhEpo for radiation- and chemotherapy-associated
anemia. In 2003, major safety issues with ESA adminis-
tration in breast cancer patients undergoing chemother-
apy were reported when a clinical trial was terminated
early because of increased mortality risks [4]. Similar
safety issues were subsequently reported in another clin-
ical trial involving patients with head and neck squa-
mous cell carcinoma (HNSCC) undergoing radiotherapy
[5]. In both trials, poor survival was identified for
patients who were treated with ESAs, mainly due to
early disease progression [4,5]. Six additional trials
observed adverse outcomes, such as decreased survival
and locoregional disease control, in ESA-treated patients
with a wide range of malignancies including lymphoid,
cervical, non-myeloid, and non-small cell lung cancer
[6]. In four of the eight aforementioned studies, patients
received chemotherapy or radiation therapy [6]. These
findings emphasize the need to understand the role of
rhEpo/EpoR signaling in cancers and evaluate the use of
rhEpo in cancer patients carefully.
More recently, a meta-analysis, utilizing data from
clinical trials evaluating erythropoiesis stimulating agents
(ESAs, as a product class) for the treatment of anemia in
the oncology setting, has further analyzed the risks of
mortality associated with administration of ESAs for
anemia in cancer patients [7,8]. The results of the analy-
sis indicated increased mortality when ESAs were admi-
nistered to cancer patients with anemia. This finding is
consistent with those reported in clinical trials that have
prospectively evaluated survival, as a primary or second-
ary outcome measure, and individually identified
increased rates of mortality or tumor progression with
the use of ESAs [7].
These major safety issues have prompted the FDA to
restrict the use of ESAs for the treatment of anemia in
cancer patients, adding ‘Warnings’ to ESAs approved
labelling information. These safety issues have also
necessitated further studies into the underlying mechan-
isms by which ESAs lead to poorer survival of cancer
patients.
There are published reports indicating that exogen-
ously administered and endogenously expressed Epo can
induce cellular invasion, promote cell proliferation and
inhibit apoptosis [9-11], but the precise role by which
rhEpo causes tumor progression in cancer patients is
unclear. Therefore, further studies are necessary to eval-
uate the role of rhEpo/EpoR in human cancers. More
specifically, rhEpo/EpoR potential functions have not
been fully explored in HNSCC cells. We have underta-
ken studies to investigate whether (i) EpoR is expressed
in established HNSCC cell lines; (ii) rhEpo promotes
cell proliferation and invasion; (iii) rhEpo protects
HNSCC cells from cisplatin-induced death, the first-line
of chemotherapy treatment for this malignancy; and (iv)
the PI3K/Akt signaling pathway is implicated in rhEpo-
mediated HNSCC cisplatin resistance.
Methods
Drugs and reagents
Recombinant human epoetin-alfa (10,000 U/ml vial) was
purchased from Amgen (Thousand Oaks, CA USA).
Cisplatin (CDDP) was purchased from Sigma-Aldrich
(St Louis, MO, USA) and a 3.33 mM stock solution was
prepared in dimethyl sulfoxide (DMSO). PI3 kinase/Akt
signaling inhibitor LY-294002 and Akt inhibitor IV were
purchased from Sigma-Aldrich and freshly dissolved in
DMSO at a stock concentration of 10 mM. Stock solu-
tions were diluted in culture media to the indicated
w o r k i n gd r u gc o n c e n t r a t i o n sprior to cell treatment.
Control cells were treated with an equal volume of vehi-
cle alone, and the concentration of DMSO in cell cul-
tures never exceeded 0.5%.
Cell lines and cell culture
Two established HNSCC cell lines, UMSCC-10B and
UMSCC-22B, were gifts from Dr. Tom Carey, University
of Michigan (Ann Arbor, MI, USA). Cell lines were cul-
tured in DMEM supplemented with 10% fetal bovine
serum (FBS), 2% streptomycin sulfate (Invitrogen, Carls-
bad, CA), and 2% L-glutamine (Invitrogen), and main-
tained at 37°C in 5% CO2 and 21% O2.
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At 90% confluence, cells were lysed and total RNA was
extracted using an RNeasy Mini kit (Qiagen, Valencia,
CA, USA). RNA was converted to cDNA using a Super-
script III Reverse Transcriptase kit (Invitrogen, Carlsbad,
CA, USA) as per the manufacturer’s instructions. The
levels of transcript for EpoR were quantified by real-
time qPCR. The primers used were custom ordered
(Operon Biotechnologies, Huntsville, AL, USA), and
sequences were as follows:
EpoR Forward: 5’-CAAGTTCGAGAGCAAAGCGG-
3’,
EpoR Reverse: 5’-TTCCTCCCAGAAACACAC-
CAAG-3’;
b-actin Forward: 5’-ACAGAGCCTCGCCTTTGC-3’,
b-actin-Reverse: 5’-CCTGGTGCCTGGGGC-3’;
Reaction mixes were prepared as triplicates and run
on the System 7300 Real-time PCR (Applied Biosystems)
using a one-step program: 95°C for 10 min, 95°C for 30
s, and 60°C for 1 min, for 40 cycles. Results were ana-
lyzed by the relative quantity (ΔΔCt)m e t h o d ,a n d
experiments were repeated at least twice independently.
b-actin gene expression was measured as endogenous
control.
Western blot analysis
For baseline levels of EpoR, HNSCC cells were serum-
starved for 24 h prior to protein extraction. To deter-
mine the effects of rhEpo on Akt phosphorylation,
HNSCC cells were serum starved for 24 h prior to treat-
ment with rhEpo at 1 U/ml for 3 or 72 h. At 90% con-
fluence, cells were lysed in RIPA lysis buffer containing
protease and phosphatase inhibitor cocktails. Total pro-
tein concentration was measured by a Bradford Protein
Assay (Bio-Rad, Hercules, CA, USA) to enable standar-
dization of protein loading. Lysate was separated on 10%
SDS-PAGE gels, and electrophoretically transferred onto
microporous polyvinylidene fluoride (PVDF) membranes
(Millipore, Bedford, MA, USA) overnight at 40 V. Mem-
branes were blocked with 5% BSA in tris-buffered saline
with 0.1% Tween-20 (TBST), then incubated with the
following primary antibodies, each at a 1:1,000 dilution,
overnight at 4°C: rabbit anti-EpoR M-20 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), mouse monoclo-
nal anti-Epo 7D10 (Santa Cruz Biotechnology), mouse
anti-b-actin (Sigma-Aldrich), rabbit total Erk (Cell Sig-
naling, Beverly, MA, USA), and rabbit anti-phospho-Akt
(Sigma-Aldrich). After a cycle of three 10-min washes
with TBST, membranes were probed with the appropri-
ate secondary antibody at 1:10,000 dilution at room
temperature for 60 min. After 3 additional washes, the
protein-antibody complexes were visualized by enzyme
chemifluorescence (Pierce, Rockford, IL, USA).
Matrigel invasion assay
Invasive properties of HNSCC cells were measured and
compared in the presence or absence of rhEpo using
Matrigel invasion assay (Becton Dickinson, Bedford,
MA). Transwell inserts of 8 μmp o r es i z ew e r ec o a t e d
with 80 μlM a t r i g e l( 1m g / m l )i nc o l ds e r u m - f r e e
DMEM. The lower chamber of the transwell was filled
with 750 μl of culture media containing 0.5% serum as
an adhesive substrate. Indicated treatments were also
added to the lower chamber. Cells were trypsinized, and
500 μlo fc e l ls u s p e n s i o n( 2×1 0
5 cells/ml) was added
in triplicate wells and allowed to incubate at 37°C for 40
h. Invading cells on the lower surface that passed
through the filter were fixed and stained using crystal
violet in gluteraldehyde and photographed. The stained
nuclei were counted (10 high-power fields per each
chamber) and averaged for each treatment. Results are
expressed as fold change in the number of invading cells
for each treatment compared to control cells. Images
were obtained using Leica DMIRE2 inverted fluores-
cence microscope. Computer program Simple PCI was
used for image capture.
Clonogenic survival assay
This assay was performed to assess potential effects of
rhEpo on cell proliferation and against cisplatin-induced
cell death in HNSCC. Cells were plated in triplicates at
500 cells per 60 × 15 mm culture plates and incubated
in DMEM supplemented with 10% FBS, L-glutamine,
and antibiotics. To test the hypothesis that rhEpo pro-
tects against cisplatin-induced cell death, UMSCC-10B
and UMSCC-22B were serum starved for 24 h and trea-
ted with rhEpo at 0, 1 or 10 U/ml. Twenty-four hours
later, the cells were exposed to 0.5 μM cisplatin for 72 h
(UMSCC-10B) or 1.0 μM cisplatin for 96 h (UMSCC-
22B). Cisplatin concentrations and incubation times
were different for the cell lines, as these parameters
were optimized for each. The media were replaced with
complete media after the time periods indicated above,
allowing the cells to recover and form colonies. Ninety-
six hours later, the cells were fixed, stained, and colonies
that contained over 50 cells were counted.
In addition, the effect of rhEpo on cell morphology
after cisplatin treatment was determined by light micro-
scopy. HNSCC cell lines were grown on cover slips,
then pre-treated with rhEpo at 1 U/ml for 24 h prior to
the addition of cisplatin for 48 h. Cells were fixed with
methanol and images were obtained using Leica
DMIRE2 inverted fluorescence microscope. Computer
program Simple PCI was used for image capture.
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To assess effects of rhEpo on cell proliferation, logarith-
mically growing HNSCC cells were trypsinized, washed,
and seeded in 96 well plates at low cell density (1,000
cells/well). After allowing the cells to adhere overnight,
varying concentrations of rhEpo (1, 10, 20 U/ml) were
added to the medium in serum free conditions for 6
days. To investigate the role of PI3K/Akt in rhEpo-
mediated cisplatin resistance, cells were plated at high
density (6,000 cells/well) and allowed to adhere over-
night. Cells were maintained in serum free conditions
then treated with or without the PI3K/Akt signaling
inhibitor LY-294002 (10 μM) or Akt inhibitor IV (1.25
μM) for 60 min prior to treatment with rhEpo at 10 U/
ml. After 24 h, cisplatin was added to the wells for 48 h.
Following the indicated incubation period for the above
assays, the number of viable cells was determined by
measuring the A490 of reduced MTS solution (Promega,
Madison, WI, USA). Data (triplicate experiments) are
expressed as the ratio of average absorbance for treated
wells to control wells, after subtracting media
absorbance.
TUNEL assay
A terminal deoxynucleotidyltransferase-mediated dUTP
nick-end-labeling (TUNEL) assay was performed to
measure apoptosis. Cells were cultured on 10-cm dia-
meter dishes, and allowed to reach 50% confluence.
After 24 h serum starvation, cells were treated with LY-
294002 (10 μM) or DMSO for 60 min prior to rhEpo
treatment (10 U/ml). After 24 h, cells were exposed to
0.5 μM cisplatin for 72 h (UMSCC-10B) or 1 μM cispla-
tin for 96 h (UMSCC-22B). Cells were harvested by
trypsinization, fixed with 1% paraformaldehyde, and
cytoplasmic DNA fragments with 3’-hydroxyl ends were
detected with an APO-Direct TUNEL kit (Phoenix Flow
Systems, San Diego, CA, USA).
Statistics
Experiments were performed in triplicate and results
represent mean and SD where appropriate. Statistical
significance of the effect of rhEpo on proliferation, inva-
sion, and survival was tested using a two sample inde-
pendent t- t e s t( 2 - t a i l e dt e s t )w i t ht h et h r e s h o l ds e ta tP
< 0.05.
Results
HNSCC cell lines UMSCC-10B and UMSCC-22B express
EpoR and endogenous Epo
Both cell lines showed expression of EpoR. MCF-7 cells,
which moderately express EpoR [12,13], were used as a
positive control for EpoR mRNA and protein expression
levels. Detected levels of EpoR mRNA in UMSCC-10B
and UMSCC-22B were 2.9- and 8.1-fold higher than
MCF-7, respectively. In both HNSCC cell lines, EpoR
protein was expressed at relatively high levels, which
correlated with mRNA data (Figure 1). In addition,
moderate levels of endogenous Epo expression were
detected in both HNSCC cell lines. The internal control
for western blots and RT-qPCR analysis was b-Actin.
RhEpo induces HNSCC cell proliferation
Pharmacological doses of rhEpo exhibited moderate
effects on cell proliferation with a maximal response at
10 U/ml. Epo at 1 U/ml increased cell proliferation by
12% and 25% in UMSCC-10B and UMSCC-22B, respec-
tively, while 10 U/ml increased proliferation by 41% and
53% (Figure 2a). Proliferative effects of rhEpo were only
apparent under serum-free conditions, and significantly
less than serum stimulation (Figure 2c). Exposure of the
UMSCC-10B and UMSCC-22B cell lines to rhEpo at 1
and 10 U/ml resulted in increased cell proliferation, as
determined by the number of colonies that had greater
than 50 cells after 7 days of culture (Figure 2b). Under
normoxic conditions in the UMSCC-10B cell line,
rhEpo at 1 U/ml produced a 1.3-fold increase in colony
formation (mean ± SD, 161 ± 22 versus 127 ± 9.7 colo-
nies), while rhEpo at 10 U/ml produced a 1.5-fold
increase in colony formation (mean ± SD, 190.0 ± 10.7
versus 127 ± 9.7). Under similar conditions in the
UMSCC-22B cell line, rhEpo at 1 U/ml showed no
appreciable effects, while rhEpo at 10 U/ml resulted in a
1.8-fold induction in colony formation (54 ± 6.8 versus
30 ± 5.5). These results indicate that rhEpo increases
cell proliferation in a concentration-dependent manner
in UMSCC-10B and UMSCC-22B cell lines after 6-7
days of culture.
RhEpo promotes in vitro invasion in HNSCC cell lines
For invasion assay, all treatments were performed with
three inserts. Addition of rhEpo at 1 U/ml increased cell
invasion by 1.8-fold in the UMSCC10B cell line and 2.6-
fold in the UMSCC-22B cell line compared with control
(Figure 3). The effect of rhEpo on cell invasion was sig-
nificant (P < 0.05) at a concentration of 1 U/ml,
although substantially less than serum stimulation (Fig-
ure 3b). These findings indicate that exposure of the
established HNSCC cell lines to rhEpo for 40 h can
increase cell invasion capabilities, consistent with find-
ings reported by other investigators that used the
UMSCC-22B cell line.
RhEpo protects HNSCC cells from cisplatin-induced cell
death
In the UMSCC-10B cells treated with 0.5 μΜ cisplatin,
exposure to rhEpo at 1 and 10 U/ml resulted in a 1.7 ± 0.2
fold (16.25 ± 3.3 colonies) and 3.0 ± 0.2 fold (29.0 ± 5.3
colonies) increase (P = 0.06) in colony number,
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rhEpo (9.75 ± 2.4 colonies). In the UMSCC-22B cell line
treated with 1.0 μM cisplatin, rhEpo at 1 U/ml resulted in
a 2.5 ± 0.1 fold (26.8 ± 1.6 colonies versus 10.5 ± 1.9 colo-
nies) increase in colony number (P < 0.05) compared to
the control cells, while rhEpo at 10 U/ml resulted in a 2.4
± 0.1 fold (24.6 ± 1.8 colonies versus 10.5 ± 1.9 colonies)
increase in colony number (P < 0.05) compared to the
control cells (Figure 4). These results indicate that rhEpo
protects HNSCC cells against cisplatin.
Inhibition of PI3K/Akt pathway mitigates rhEpo-mediated
cytoprotective effects
A ss h o w ni nF i g u r e5 aa n d5 b ,e x p o s u r et or h E p o
resulted in a significant increase in Akt activation in
both cell lines, which was dependent on PI3K. RhEpo-
A 
B 
59 kDa
β-actin  42 kDa 
EpoR
MCF7 UMSCC-10B  UMSCC-22B 
C 
22B 
37 kDa 
42 kDa 
MCF7 10B 
β-actin 
 
Endogenous Epo
Figure 1 EpoR and endogenous Epo expression in two established HNSCC cell lines. a Quantitative polymerase chain reaction (qPCR) and b
Western blot analysis demonstrating the expression of EpoR in two established cell lines. c Western blot analysis also indicates UMSCC-10B and
UMSCC-22B express moderate levels of endogenous Epo. MCF-7 cells were used as a positive control for EpoR and endogenous Epo expression.
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tained for at least 72 h. To further investigate the role
of Akt in the protective effects of rhEpo, the cell lines
were exposed to cisplatin with or without rhEpo and
Akt inhibitor IV, and cell viability was measured by
MTS assay (Figure 5c). RhEpo protected cells from cis-
platin-induced death, reducing loss of cell viability by
39.9% and 56.0% in UMSCC-10B and UMSCC-22B,
respectively, compared to cisplatin alone. Pre-treatment
with Akt specific inhibitor IV resulted in a 69.6% and
61.2% reduced protection of rhEpo-treated UMSCC-10B
and UMSCC-22B cells exposed to cisplatin, respectively.
Treatment with LY-294002 (PI3K/Akt signaling inhibi-
tor) resulted in a similar inhibition of rhEpo-mediated
cytoprotection (63.0% and 71.7% reduced protection in
UMSCC-10B and UMSCC-22B, respectively). Treatment
of cells with drug vehicle, Akt inhibitor IV, or LY-
294002 resulted in less than 5% decrease in cell viability
compared to untreated cells. In a similar experiment, a
TUNEL assay was performed to measure cell death.
When cisplatin was combined with rhEpo, a 76.5%
reduction in cell death was observed in UMSCC-22B
cells and a 30.5% reduction in cell death was observed
in UMSCC-10B (P < 0.05) (Figure 5d). However, when
cells were exposed to rhEpo, cisplatin, and 10 μML Y -
294002, UMSCC-10B experienced a 9.4% reduction in
cell death compared to cisplatin alone. That is, 69.4%
less effective in protecting cells from cisplatin-induced
cell death than rhEpo alone. Under the same conditions,
UMSCC-22B experienced a 37.3% reduction in cell
death compared to the cisplatin alone, about 51% less
effective in protecting cells than rhEpo alone. Control
cells exposed to drug vehicle, cells exposed to rhEpo,
and cells exposed to rhEpo and LY-294002 experienced
less than 1% cell death in both cell lines.
Discussion
ESAs are highly effective in treating anemia, a frequent
side effect of chemotherapy. But major safety issues
reported in recent clinical trials have dampened the
enthusiasm in the use of ESAs, and have raised legiti-
mate concerns regarding the routine use of ESAs for
treatment of anemia in cancer patients. For instance,
two trials that evaluated the potential for ESAs to
improve overall or progression-free survival in cancer
patients reported in 2003 an increased risk of mortality
in patients with breast cancer who were treated with
ESA and chemotherapy [4], as well as poor survival in
patients with HNSCC who received ESA and radiother-
apy [5]. Other published reviews of safety information
A  B 
C 
Figure 2 Effects of rhEpo on cell proliferation. RhEpo promotes moderate cell proliferation under serum free conditions as measured by a
colorimetric MTS assay and b colony formation assay in UMSCC-10B and UMSCC-22B. c In the presence of low or moderate levels of serum,
rhEpo failed to modulate cell proliferation.
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Figure 3 Effects of rhEpo on invasion. RhEpo functions as a chemoattractant for HNSCC cell lines under study, promoting in vitro invasion. a
Exposure of cells to rhEpo at 1 U/ml for 40 h increased invasion by 80% in UMSCC10B and 160% in UMSCC-22B compared to their respective
controls. b Images of representative fields showing an increase in the number of Matrigel invading cells upon administration of rhEpo, although
less significant than serum stimulation. Magnification = 100 ×.
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tumor progression and mortality in patients adminis-
tered ESAs [6,7,14,15]. Although rhEpo has been impli-
cated in the regulation of tumor growth, the precise role
of rhEpo/EpoR in human cancers is not well
understood.
In the present study, we utilized two established
HNSCC cell lines to characterise the contribution of
rhEpo/EpoR signaling to cell proliferation, invasion and
apoptosis. Both cell lines were shown to express EpoR
by qPCR and western blot analysis. EpoR protein was
expressed at relatively high levels in both cell lines,
which was confirmed by mRNA data. EpoR expression
was higher in UMSCC-22B than UMSCC-10B cell line.
The difference in EpoR expression between the two cell
lines may be related to the slightly higher tumor grade
of UMSCC-22B [16,17]. It should be pointed out that
the selectivity/specificity of antibodies used for the
detection of functional EpoR is an important considera-
tion. It seems the specificity of commercial EpoR antibo-
dies is under speculation. However, Elliott et al. has
recently demonstrated that the M-20 antibody is capable
of detecting EpoR through western blot analysis [12].
The effect of rhEpo on cell proliferation was investi-
gated through MTS and clonogenic assays. Our findings
indicate that rhEpo increases proliferation in a
A 
CDDP  CDDP + Epo 1 U/ml  CDDP + Epo 10 U/ml  B 
Figure 4 RhEpo protects HNSCC cell lines against cisplatin-induced cell death. a Clonogenic assay demonstrating that in UMSCC-10B cells
treated with 0.5 μM cisplatin, exposure to rhEpo at 1 and 10 U/ml resulted in a 1.7 ± 0.2 fold and 3.0 ± 0.2 fold increase in colony number,
compared to control cells not exposed to rhEpo, respectively. In cell line UMSCC-22B treated with 1.0 μM cisplatin, rhEpo at 1 U/ml resulted in a
2.5 ± 0.1 fold increase in colony number compared to the control cells. b Micrographs of representative fields showing the cytoprotective effects
of rhEpo on cell morphology after cisplatin treatment. Shrunken cytosol and fragmentation of cells into apoptotic bodies, depicted in the far left
micrograph, was noticeably reduced upon exposure to rhEpo at 1 and 10 U/ml. Scale bar represents 50 μm.
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Figure 5 Akt activation by PI3K is involved in rhEpo-mediated cisplatin resistance. a Western blot analysis demonstrating that exposure to
1 U/ml of rhEpo induces Akt activation in both UMSCC-10B and UMSCC-22B cell lines which is sustained for at least 72 h. b RhEpo-mediated Akt
phosphorylation is dependent on PI3K, as determined by western blot analysis. Cells were pre-treated with either drug vehicle, 10 μM LY-294002,
or 1.25 μM Akt inhibitor IV for 60 min prior to rhEpo treatment for 3 h. Total Erk was used as loading control. c MTS assays used to measure cell
viability in UMSCC-10B and UMSCC-22B upon exposure to cisplatin and rhEpo show a 39.9% and 56.0% reduction in loss of cell viability when
compared to cisplatin alone, respectively. Pre-treatment with Akt inhibitor IV resulted in a 69.6% and 61.2% reduced protection of rhEpo-treated
UMSCC-10B and UMSCC-22B, respectively, and treatment with LY-294002 resulted in a 63.0% and 71.7% reduced protection. d TUNEL assays
used to measure cell death in UMSCC-10B (top panel) and UMSCC-22B (bottom panel) reveal a significant reduction in cell death when treated
with rhEpo and cisplatin (iii) when compared to cisplatin alone (ii), a 30.5% and 76.2% reduction in cell death, respectively. UMSCC-10B and
UMSCC-22B cells exposed to rhEpo, cisplatin, and LY-294002 (PI3K/Akt signaling inhibitor) experienced a 69.2% and 50.9% reduced protection,
respectively. Cells treated with only LY-294002 (i) experienced very little cell death (2-5%) while control cells exposed to drug vehicle, cells
exposed to rhEpo alone, and cells exposed to rhEpo and LY-294002, experienced less than 1% cell death.
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UMSCC-22B cell lines at pharmacologic doses. As these
cell lines showed high expression of EpoR and enhanced
proliferative ability under rhEpo exposure, it is likely
that the rhEpo effects are mediated through the activity
of EpoR. Lai et al. reported a limited effect on HNSCC
proliferation at the 1 U/ml dose, while higher pharma-
cologic doses (10-100 U/ml) of rhEpo were required to
achieve a measurable proliferation response [9]. Other
investigators have found only a limited or no effect on
cell proliferation upon exposure to rhEpo by evaluating
EpoR positive cell lines, human melanoma cells, or
other non-hematopoietic cancer cell lines [18-20]. This
suggests that the proliferative effects of rhEpo may be
cell type specific and dependent on whether cells
express functional Epo receptors. A study by Hardee et
al. [21] similarly showed no proliferative advantage to a
HNSCC cell line FaDu when exposed to rhEpo in vivo.
The lack of response may be attributed to low or no
expression of EpoR, as the EpoR levels in FaDu are
unclear. Also, during the in vivo experiments, it is nota-
ble that rhEpo was administered only after a 200 mm
3
tumor was achieved [21]. We hypothesize that rhEpo-
induced cell proliferation may be restricted to stages of
initial tumor development.
The results of our invasion assay showed that expo-
sure of the established cell lines to rhEpo induced a
more robust invasion in HNSCC cells. This finding is
consistent with the results reported by Lai et al. and
M o h y e l d i ne ta l .w h od e m o n s t r a t e dt h a tr h E p op r o -
motes invasion using a Matrigel invasion assay [9,10].
The increased invasion was shown by both investigators
to be through the Janus kinase-Signal transducer and
transcription (JAK-STAT) pathway [9,10]. As the major-
ity of head and neck cancer related morbidity is a result
of local invasion and extension of the solid tumor, these
findings indicate that rhEpo-induced invasion may have
contributed to the primary or secondary outcome mea-
sures of the HNSCC patients trial [5], in which patients
experienced increased locoregional recurrence and
decreased survival when treated concomitantly with
rhEpo [5]. In another study, EpoR expression in neuro-
blastoma primary tumors has been shown to have signif-
icantly lower expression when compared to paired
lymph node metastases, a further indication that EpoR
is highly implicated in metastasis [22].
Coexpression of EpoR and endogenous Epo has been
detected in a variety of primary cancers and tumor cell
lines, including non-small cell lung cancer, breast can-
cer, and cervical cancer [1]. In certain cancers, such as
uterine, ovarian, melanoma, and stomach choriocarci-
noma, inhibition of this autocrine/paracrine Epo/EpoR
signaling pathway altered critical aspects of tumor biol-
ogy, including inhibited proliferation and increased
apoptotic cell death [1]. Our data demonstrating endo-
genous Epo expression in UMSCC-10B and UMSCC-
22B indicates the possible existence of an Epo/EpoR
autocrine/paracrine neoplastic pathway which promotes
malignant progression of HNSCC, further propagated by
administration of exogenous rhEpo. As a result, the lim-
ited effect on cell proliferation and invasion of exogen-
ously added rhEpo may be a consequence of the
moderately high basal levels of Epo present in both cell
lines. Thus, in the absence of endogenous Epo, the
pharmacological doses used in this study may have
induced a more pronounced effect on cell growth and
invasion than observed. Further studies should be
devoted to studying the effects of endogenous Epo
expression on regulating a malignant phenotype in
HNSCC.
In addition to promoting cell proliferation and inva-
sion, it is also possible that rhEpo inhibits apoptosis in
cancer cells. RhEpo has been shown to induce anti-
apoptotic genes including Bcl-xL, Bcl-2,a n dMcl-1 in
Ewing sarcoma and neuroblastoma cell lines [23]. It has
also been reported that rhEpo decreased apoptosis when
melanoma cells were exposed to darcarbazine and cispa-
tin, and increased the surviving fraction of cervical car-
cinoma cells treated with cisplatin [24,25]. Belenkov et
al. also reported resistance of malignant glioma and pri-
mary cervical cancer lines to radiation and cisplatin-
induced cell death upon addition of rhEpo [26]. This
finding was mitigated and reversed upon addition of a
Jak2 inhibitor [26]. More recently, it has been demon-
strated that both hypoxia and rhEpo protect glioblas-
toma multiform cells from cisplatin cytotoxicity [27]. In
contrast, others have demonstrated that rhEpo sensitizes
human renal cell carcinoma and myelomonocytic leuke-
mia cell lines to daunorubicin and vinblastine through
inhibition of the NF-kappa b pathway [28]. Furthermore,
Palumbo et al. showed that rhEpo fails to modulate
pemetrexed or cisplatin sensitivity of EpoR expressing
mesothelioma cell lines, despite phosphorylating Akt
[29].
We are the first to address the specific in vitro effects
of rhEpo on HNSCC survival when administered
together with cisplatin, using colony formation assays.
These experiments are especially important, as the col-
ony formation assay is most relevant in determining the
long-term protective effects of rhEpo, particularly when
clinical doses of rhEpo and cisplatin are used. Our study
indicates that the addition of rhEpo mitigates the pro-
apoptotic effects of cisplatin, rendering this first-line
HNSCC drug significantly less effective. The intracellu-
lar mechanism of the Epo ligand binding to its receptor
is well documented. EpoR is a ubiquitous membrane
receptor, and when Epo binds, the EpoR receptor homo-
dimerizes, regulating activation of the PI3K/Akt signal
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Page 10 of 12transduction pathway [30]. We further investigated the
potential role of Akt in the protective effects of rhEpo.
Exposure to rhEpo resulted in a significant increase in
Akt activation in both cell lines. The fact that direct
inhibition of Akt produced results comparable to PI3K
inhibition (with LY-294002) indicates that the observed
effects of LY-294002 are due to interruption of the
PI3K/Akt signaling pathway. Collectively, the data impli-
cates Akt activation in the cytoprotective effects of
rhEpo against cisplatin-induced death. However, as the
PI3K and Akt inhibitors did not completely block the
cytoprotective effects of rhEpo, it is likely that rhEpo
activation of other signaling pathways, such as JAK2/
STAT5, contributes to the observed cisplatin resistance.
Our results suggest p-Akt may play a pivotal role in
the protective effects of rhEpo. This is consistent with
the findings of several groups that rhEpo’se f f e c t sa r e
mediated in part through the PI3K/Akt pathway [31-33].
Further investigation is needed to elucidate the role of
PI3K/Akt signaling in rhEpo-induced resistance.
Conclusions
The results demonstrate that, in HNSCC cells expres-
sing functional EpoR, rhEpo promotes invasion, cell pro-
liferation, and induces resistance to cisplatin, which may
contribute to tumor progression. Modulation of the
response of HNSCC cells to cisplatin may significantly
contribute to the adverse effects seen in HNSCC
patients receiving rhEpo. Given the results of this study
and the broad signaling of the EpoR cascade, it is unli-
kely that the decrease in patient survival can be attribu-
ted to a single source. Currently, the relative importance
of these mechanisms is yet to be elucidated. We propose
further studies to investigate the effect of rhEpo in vivo
in xenograft mouse models to determine the relative
effects of these mechanisms.
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